Central nervous system (CNS) leukemia after imatinib mesylate therapy for chronic myelogenous leukemia (CML)

被引：0
|
作者：
Solh, M. M.
Kantarjian, H.
O'Brien, S.
Giles, F.
Faderl, S.
Garcia-Manero, G.
Rios, M.
Shan, J.
Cortes, J.
Ravandi-Kashani, F.
机构：
[1] Wayne State Univ, Detroit Med Ctr, Detroit, MI USA
[2] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2007年 / 25卷 / 18期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7042
引用
收藏
页数：1
相关论文
共 50 条
  • [41] IMATINIB MESYLATE IN NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA (CML) PATIENTS
    Ionita, H.
    Ionita, I.
    Cheveresan, M.
    Iordache, M.
    Cheveresan, L.
    Ionita, M.
    Borzak, G.
    Ionita, C. O.
    Pascalau, A.
    Calamar, D.
    Oros, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 548 - 548
  • [42] Experience with imatinib mesylate in children with Ph+ chronic myelogenous leukemia
    Kapoor, Gauri
    Abedin, Sarfrazu
    Garg, Pravesh
    Tyagi, Vinod
    Khullar, Paras
    PEDIATRIC BLOOD & CANCER, 2007, 49 (04) : 528 - 528
  • [43] Approval summary for imatinib mesylate capsules in the treatment of chronic myelogenous leukemia
    Cohen, MH
    Williams, G
    Johnson, JR
    Duan, J
    Gobburu, J
    Rahman, A
    Benson, K
    Leighton, J
    Kim, SK
    Wood, R
    Rothmann, M
    Chen, G
    U, KM
    Staten, AM
    Pazdur, R
    CLINICAL CANCER RESEARCH, 2002, 8 (05) : 935 - 942
  • [44] Imatinib Mesylate in Combination with Other Chemotherapeutic Agents for Chronic Myelogenous Leukemia
    Tetsuzo Tauchi
    Kazuma Ohyashiki
    International Journal of Hematology, 2004, 79 : 434 - 440
  • [45] Significance of marrow fibrosis in chronic phase chronic myelogenous leukemia (CML) post interferon-a failure treated with imatinib mesylate therapy.
    Alvarez, RH
    Kantarjian, HM
    Bueso-Ramos, C
    Talpaz, M
    O'Brien, S
    Giles, F
    Rios, MB
    Shan, JQ
    Cortes, J
    BLOOD, 2004, 104 (11) : 803A - 803A
  • [46] A Case of Isolated Lymphoblastic Relapse of the Central Nervous System in a Patient with Chronic Myelogenous Leukemia Treated with Imatinib
    Park, Mi-Jung
    Park, Pil-Whan
    Seo, Yiel-Hea
    Kim, Kyung-Hee
    Seo, Ja-Young
    Jeong, Ji-Hun
    Kim, Moon Jin
    Jeong, Jin-Woo
    Ahn, Jeong-Yeal
    Park, Jinny
    ANNALS OF LABORATORY MEDICINE, 2014, 34 (03) : 247 - 251
  • [47] Myelodysplastic syndromes and acute leukemia developing after imatinib mesylate therapy for chronic myeloid leukemia
    Kovitz, Craig
    Kantarjian, Hagop
    Garcia-Manero, Guillermo
    Abruzzo, Lynne V.
    Cortes, Jorge
    BLOOD, 2006, 108 (08) : 2811 - 2813
  • [48] Subcutaneous (SC) homoharringtonine (HHT) for patients (pts) with chronic myelogenous leukemia (CML) in chronic phase (CP) after imatinib mesylate failure.
    Quintas-Cardama, A
    Cortes, J
    Verstovsek, S
    Laddie, N
    Estrov, Z
    Kantarjian, H
    BLOOD, 2005, 106 (11) : 290B - 290B
  • [49] Complete molecular remission in chronic myelogenous leukemia after imatinib therapy
    Barbany, G
    Höglund, M
    Simonsson, B
    NEW ENGLAND JOURNAL OF MEDICINE, 2002, 347 (07): : 539 - 540
  • [50] Interleukin 11 May improve thrombocytopenia associated with Imatinib mesylate therapy in chronic Myelogenous leukemia
    Ault, P
    Kantarjian, H
    Welch, MA
    Giles, F
    Rios, MB
    Cortes, J
    LEUKEMIA RESEARCH, 2004, 28 (06) : 613 - 618
12345